Pioneers of peripheral medicine
Cook has worked alongside the pioneers of peripheral medicine for 60 years and remain dedicated to providing therapies and technologies that treat peripheral arterial and venous diseases. Globally, these impact millions of patients and require specialized devices and treatment options to improve patients’ quality of life.
Peripheral Arterial Disease (PAD) often occurs in the legs and can lead to amputation; those with the disease have a greater risk of suffering a heart attack or stroke.1 Cook provided the first drug-eluting-stent, Zilver® PTX®, has shown predictable results and is the only stent with published five-year data.2 Patients with PAD below the knee can be challenging to treat, our goal is to serve as a procedural partner in treating this disease. We have designed devices to increase efficiency, improve outcomes, and preserve limbs.
Venous disease is complex and can impact patients of younger and more diverse backgrounds than other vascular diseases. We are committed to helping all patients affected by deep venous disease by building awareness of the symptoms that can progress to pulmonary embolism or venous obstruction and developing therapies to treat them.
Cook delivers a comprehensive offering of introducer sets, wire guides, sheaths, catheters, balloons, and stents that enable physicians to effectively access, target, and treat these diseases. We offer a full line of filters and retrieval sets for the prevention of recurrent pulmonary embolism (PE).
- Facts about peripheral arterial disease (PAD). National Heart, Lung, and Blood Institute. NIH Publication No. 21-HL-5837; December 2021.
- Dake MD, Ansel GM, Jaff MR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016; 133(15):1472–1483.
![](https://www.cookmedical.com/wp-content/uploads/sites/11/2024/07/Screenshot-2024-07-25-at-1.44.21 PM-150x150.png)
While the treatment of venous obstruction has seen significant advancements in recent years, there continues to be a lack of robust evidence or standardized best practices for venous specialists to follow. This has been particularly challenging for those managing lower…
Study suggests effective treatment of symptomatic iliofemoral venous outflow obstruction1 The study, “Twelve-month end point results from the evaluation of the Zilver Vena venous stent in the treatment of symptomatic iliofemoral venous outflow obstruction (VIVO clinical study),” has shown that…
An interview with Dr. Eric Secemsky Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM Director of Vascular Intervention, Beth Israel Deaconess Medical Center Section Head, Interventional Cardiology and Vascular Research, Smith Center for Outcomes…
Watch videos below while the experts talk about treatment trends, product features, and usage “If I want to just get some good distal flow and I want to get into those tibials, the Serenity balloon is my mainstay.” …
The FDA released a letter to health care providers titled, “August 7, 2019 UPDATE: Treatment of Peripheral Arterial Disease with Paclitaxel-Coated Balloons and Paclitaxel-Eluting Stents Potentially Associated with Increased Mortality.” The FDA letter is a follow-up to a June 19-20…
Cook’s 2nd generation CXI Support Catheter has earned its reputation as a premium technology for your procedural essentials in Peripheral Arterial Disease (PAD) cases. Cook Medical launched the new 2.6 Fr catheter on March 25, 2019, in the U.S. and…
With a new 5 mm diameter stent added to the Zilver PTX arsenal, Cook Medical has expanded its offering of the broadest range of drug-eluting stent (DES) sizes available to treat peripheral arterial disease (PAD) in the superficial femoral artery…
Peripheral arterial disease (PAD) is a serious condition that affects 8-12 million Americans each year.1 PAD occurs when fatty deposits form in arteries that are outside of your heart. These fatty deposits (or plaque) can restrict the flow of blood.…
On March 25, Cook Medical launched the new 2.6 Fr CXI® Support Catheter with platinum-iridium marker bands. The new 2.6 Fr CXI, which is now available in the US and Canada, comes with additional tip configurations and a new 135…
On Dec. 6, Dr. Konstantinos Katsanos and his coauthors created tremendous controversy when they published a meta-analysis on paclitaxel-coated balloons and stents in the Journal of the American Heart Association. Using data from 28 randomized controlled trials (RCT), the authors…
Zilver® PTX® global data analysis reveals proven long-term benefit, real-world outcomes1 On Nov. 6, Dr. Michael Dake, senior vice president for University of Arizona Health Sciences, presented results from a global data analysis on Zilver PTX at VIVA (Vascular InterVentional…
Cook Medical is excited to invite you to attend a talk during the PAD Luncheon at VIVA 2018. Title: “The first DES gets the last word: unmatched evidence supports the first FDA-approved SFA drug-eluting stent” Topic covered: Understanding the basics of…
Visit our booth, #400, and come chat with us in our Cook Vascular Suite in Lafite 1. And we cordially invite you to attend our AORTIC Armageddon Luncheon and PAD Luncheon talks. AORTIC Armageddon Luncheon Title: “Achieving durable endovascular aortic…
![](https://www.cookmedical.com/wp-content/uploads/sites/11/2018/09/D44921_feature_image-150x150.jpg)
Cook Medical is excited for VEINS at VIVA 2018. We hope you’ll visit our booth to learn what we’re up to in the world of venous endovascular interventional strategies. Stop by to chat with our staff and discuss all things…
![](https://www.cookmedical.com/wp-content/uploads/sites/11/2018/04/beacon_bunch_280-150x150.jpg)
The best medical device technology is only as good as a customer’s ability to use it safely and effectively. Usability testing is the key to ensuring medical devices are…
![](https://www.cookmedical.com/wp-content/uploads/sites/11/2017/10/pardon_the_intervention_280-150x150.jpg)
NEW lunch sessions! Get lunch and grab a seat. Listen to clinical experts engaging in lively debate on the hottest topics in the vascular world. Pardon the Intervention will take place Tuesday-Friday, from 12 noon to 1 pm, in the…